Reforming direct-to-consumer advertising

Nature Biotechnology

Volumn 29, Issue 5, 2011, Pages 397-400

  Liang, Bryan A ^a   MacKey, Tim ^b  

^a University of California   (United States)

^b CALIFORNIA WESTERN SCHOOL OF LAW   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CONSUMER; DRUG INDUSTRY; DRUG LEGISLATION; DRUG MARKETING; INFORMATION DISSEMINATION; LAW; NOTE; PATIENT EDUCATION; PATIENT MONITORING; PATIENT SAFETY; PRIORITY JOURNAL; UNITED STATES;

ADVERTISING AS TOPIC; CONSUMER PRODUCT SAFETY; DRUG INDUSTRY; DRUG PRESCRIPTIONS; HUMANS; MARKETING; RISK FACTORS; UNITED STATES; UNITED STATES FOOD AND DRUG ADMINISTRATION;

EID: 79955784037     PISSN: 10870156     EISSN: 15461696     Source Type: Journal    
DOI: 10.1038/nbt.1865     Document Type: Note

References (27)

1. Wolfe, S. N. Engl. J. Med. 346, 524-526 (2002).
2. http://www.kff.org/rxdrugs/loader.cfm?url=/commonspot/ security/getfile.cfm&PageID=14378
3. Kuehn, B. J. Am. Med. Assoc. 303, 311-313 (2010).
4. Lurie, P. J. Law Med. Ethics 37, 444-450 (2009).
5. http://edocket.access.gpo.gov/2010/pdf/2010-6996. pdf
6. Mack, J. Nat. Biotechnol. 24, 267 (2006).
7. Anonymous. Bulletin of the World Health Organization. 87 (2009).
8. Anonymous. Prescription Drugs: Improvements Needed in FDA's Oversight of Direct-to-Consumer Advertising. i-48 (US Government Accountability Office, Washington, DC, 2006). .
9. Donohue, J.M., Cevasco, M. & Rosenthal, M.B. N. Engl. J. Med. 357, 673-681 (2007).
10. Anonymous. Impact of Direct-to-Consumer Advertising on Prescription Drug Spending (The Henry J. Kaiser Family Foundation, 2003). .
11. Law, M. et al. Br. Med. J. 337, a1055 (2008).
12. Mackenzie, F.J. et al. Intern. Med. J. 37, 224-228 (2007).
13. Velo, G. & Moretti, U. Br. J. CLin. Pharmacol. 66, 626-628 (2008).
14. Frosch, D.L. et al. Ann. Fam. Med. 5, 6-13 (2007).
15. Frosch, D.L. et al. Am. J. Public Health 100, 24-32 (2010).
16. Vastag, B. Nat. Biotechnol. 25, 267 (2007).
17. Evans, D. Pfizer broke the law by promoting drugs for unapproved uses. Bloomberg (9 November 2009). .
18. Anonymous. Drug Safety: FDA Has Begun Efforts to Enhance Postmarket Safety, but Additional Actions Are Needed. i-49 (US Government Accountability Office, Washington, DC, 2009).
19. Singer, N. Lawmakers seek to curb drug commercials. New York Times (27 July 2009). .
20. Shuchman, M. N. Engl. J. Med. 356, 2236-2239 (2007).
21. Liang, B.A. & Mackey, T. Science 327, 273-274 (2010).
22. http://www.ashp.org/menu/News/PharmacyNews/ NewsArticle.aspx?id=3426.
23. Anonymous. Guidance for Industry Format and Content of Proposed Risk Evaluation and Mitigation Strategies (REMS), REMS Assessments, and Proposed REMS Modification. (US HHS, FDA, CDER, CBER, 2009) .
24. CFR 310.305.
25. Couzin, J. Science 307, 196-198 (2005).
26. Woloshin, S., Schwartz, L. & Welch, H. Health Aff. W4, 234-245 (2004).
27. Rodwin, M.A. N. Engl. J. Med. 321, 1405-1408 (1989).